… Pharmacological inhibitors of p38 suppress inflammation and are … p38 activation in the
heart. The purpose is to evaluate p38 inhibition as a potential therapy for ischaemic heart …

The p38-MAPK pathway plays an important role in myocardial ischaemia/reperfusion injury
and has been … The activation of p38-MAPK by dual phosphorylation during myocardial …

… activated p38 family member. However, understanding remains limited of how the different
p38 … In this review, we summarize current knowledge of p38 function in the heart and discuss …

… , JNKs, p38-MAPK(s) and ERKs are expressed in the human heart and the activities of
JNKs and p38-MAPK(s) were increased in heart failure secondary to ischaemic heart disease. …

… an increase in p38 MAPK activation during sustained ischaemia, similar to … p38 MAPK
activation during sustained ischaemia of both ischaemic and β-adrenergic preconditioned hearts …

… However, whether p38 MAPK inhibition during ischemia or reperfusion provides … We tested
the hypothesis that p38 MAPK inhibition at different times during I/R protects the heart from …

… To test whether the phosphorylation of p38 MAPK could be the site of the blockade of
genistein, we activated p38 MAPK with anisomycin and tested whether genistein could block the …

… of p38 MAPK protects the heart against ischaemic damage.In fact, p38 MAPK activation has
… , indicates that its activation is indeed detrimental to the ischaemic heart. This seems logical …

… When p38-MAPK is in the non-dual, phosphorylated, inactive … non-dual phospho-form of
p38-MAPK is inactive as a result of … Role of G proteins and modulation of p38 MAPK activation in …

… during sustained ischaemia in comparison with the controls. In conclusion the activation of
p38 MAPK during lethal ischaemia, but not during the ischaemic preconditioning protocol, is …